Motric Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Motric Bio is a private, pre-revenue biotech company advancing a selective myosin-2 inhibitor platform for movement disorders. Its lead asset, MTR-601, has completed a Phase 1 safety study and is now in Phase 2 development for cervical dystonia. The company is an Aditum Bio portfolio company, founded following the in-licensing of its lead candidate, and is targeting a significant unmet need in neurological conditions characterized by chronic muscle overactivity.

Movement DisordersNeurology

Technology Platform

Selective myosin-2 inhibitors targeting fast skeletal muscle contraction.

Opportunities

A successful oral therapy for cervical dystonia could disrupt the injectable botulinum toxin market by offering greater convenience and continuous symptom control.

The myosin inhibitor platform also has potential for expansion into larger indications like spasticity, which affects millions of patients globally and lacks optimal oral treatments.

Risk Factors

The primary risk is clinical failure of MTR-601 in its ongoing Phase 2 trial, as the novel mechanism is unproven in patients.

The company also faces commercial risk in convincing physicians to switch from established injectable standards of care and is dependent on continued funding from its parent organization.

Competitive Landscape

Motric Bio competes in a market dominated by injectable botulinum toxin products (e.g., AbbVie's Botox, Ipsen's Dysport) for cervical dystonia and oral CNS-acting muscle relaxants (e.g., baclofen) for spasticity. Its differentiation lies in its oral route of administration and a novel, peripherally-acting mechanism aimed at reducing side effects.

More companies in Small Molecule Drugs →More companies in United States →